KIDS icon

OrthoPediatrics

21.68 USD
-0.59
2.65%
At close Jul 30, 4:00 PM EDT
After hours
21.68
+0.00
0.00%
1 day
-2.65%
5 days
-8.14%
1 month
0.93%
3 months
4.13%
6 months
-10.19%
Year to date
-5.20%
1 year
-32.78%
5 years
-49.35%
10 years
12.80%
 

About: OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.

Employees: 562

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

500% more call options, than puts

Call options by funds: $12K | Put options by funds: $2K

75% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 12

7% more capital invested

Capital invested by funds: $383M [Q4 2024] → $411M (+$28.6M) [Q1 2025]

6% more funds holding

Funds holding: 108 [Q4 2024] → 115 (+7) [Q1 2025]

0.59% more ownership

Funds ownership: 68.13% [Q4 2024] → 68.72% (+0.59%) [Q1 2025]

8% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 38

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$30
38%
upside
Avg. target
$36
66%
upside
High target
$42
94%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Matt O'Brien
38%upside
$30
Overweight
Maintained
8 May 2025
Needham
Mike Matson
94%upside
$42
Buy
Reiterated
8 May 2025

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 5, 2025
WARSAW, Ind., July 22, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2025 financial results on August 5, 2025 after the market closes.
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 5, 2025
Neutral
GlobeNewsWire
2 weeks ago
Global POISE Study Reaches Milestone of 600 Orthopedic Implants in Pediatric Patients, Advancing Research on the Safety and Efficacy of OrthoPediatrics® Products
WARSAW, Ind., July 16, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced a significant milestone in the ongoing Global POISE (Pediatric Orthopedic Implant Safety and Efficacy) Study: more than 600 implants are now being observed across 300+ pediatric patients as part of this study.
Global POISE Study Reaches Milestone of 600 Orthopedic Implants in Pediatric Patients, Advancing Research on the Safety and Efficacy of OrthoPediatrics® Products
Neutral
GlobeNewsWire
2 months ago
OrthoPediatrics Corp. Continued Leading Sponsorship at 2025 POSNA Annual Meeting
WARSAW, Ind., May 14, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the 2025 Pediatric Orthopaedic Society of North America (“POSNA”) annual meeting as an Emerald Sponsor.
OrthoPediatrics Corp. Continued Leading Sponsorship at 2025 POSNA Annual Meeting
Neutral
Seeking Alpha
2 months ago
OrthoPediatrics Corp. (KIDS) Q1 2025 Earnings Call Transcript
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group, IR David Bailey - President and CEO Fred Hite - Chief Operating and Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Rick Wise - Stifel Ben Haynor - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the OrthoPediatrics Corporation First Quarter 2025 Earnings Conference call.
OrthoPediatrics Corp. (KIDS) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Negative
Zacks Investment Research
2 months ago
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025.
OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
Neutral
GlobeNewsWire
2 months ago
OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company's 5th FDA approval in 2025.
OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System
Neutral
GlobeNewsWire
3 months ago
OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025
WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes.
OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025
Neutral
GlobeNewsWire
3 months ago
OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company's 80th system designed to treat musculoskeletal issues in children.
OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
Charts implemented using Lightweight Charts™